X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

Content Team by Content Team
18th March 2023
in Clinical Trials, News

The combination of modulator therapies tezacaftor (TEZ) and ivacaftor (IVA) for cystic fibrosis (CF) has shown long-term safety as well as clinical benefit in a trial that lasted four years.

Both the CF modulators were assessed across the age group of 12 years and older. The participants of the study tolerated the combination regimen over a period of 96 weeks. These patients, apparently, had already participated in a 120-day trial when it came to the same combination.

As far as the recent study was concerned, the enhancements achieved throughout the earlier trial were maintained. Hence, the recent study shows tezacaftor, along with ivacaftor, could work in the long term.

The protein called cystic fibrosis transmembrane regulator, or CFTR, takes control of the movement of water when it comes to the lung tissues. This goes on to allow a thin and free-flowing production of the mucus.

Apparently, IVA happened to be the first small molecule that targeted the CFTR protein directly. It attaches itself to the CFTR protein at the surface of the cell, thereby holding the gates of the channel open and also keeping the channel of the protein open for a longer time so as to allow the water movement as well as decrease the mucus’ thickness. That said, this drug happens to be appropriate only for those people who have a mutation that goes on to produce proteins at the surface of the cell, which does not take place in patients with F508del.

Referred to as a corrector, TEZ binds itself to the CFTR protein and enables the protein to maintain its shape so that it can operate better. This is significant for those with F508del, as it can very well elevate the quantity of the protein present at the cell’s surface, where it can be acted upon by the IVA.

The IVA approval in 2012 made a significant breakthrough in treating the disease. It gave out a new class of CF drugs named modulators that addressed underlying problems in CF rather than just treating the sequelae of CF. When the patients were treated with a mix of CF modulators targeting the function as well as the structure of the protein, the effects were even greater.

While the clinical trial was still being conducted, a three-part section that comprised of TEZ, IVA, as well as elexacaftor was approved in 2019. It has since become the care standard.

As per the Medical University of South Carolina’s Dr. Patrick Flume, with TEZ and IVA, one can see a surge of around 2–3 percent in lung function in patients with CF. On the other hand, the triple therapy will go on to see more than a 15% improvement in the function of the lungs.

In conclusion, the findings also show that the mixed modulator therapy is well tolerated and safe in the long term, showing that two of the three drugs in the standard therapy can be used in a safe manner over time.

Previous Post

SVB Collapse And Its Implications On Biotechnology Sector

Next Post

MHRA In The UK To Assess Stem Cell Robots For Cell Therapies

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
T2 Biosystems T2SARS-CoV-2 Panel Detects Omicron Subvariants

MHRA In The UK To Assess Stem Cell Robots For Cell Therapies

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In